Deferred Tax Assets, Valuation Allowance in USD of Can-Fite BioPharma Ltd. from Q4 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Can-Fite BioPharma Ltd. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2018 to Q4 2024.
  • Can-Fite BioPharma Ltd. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $28.1M, a 5.24% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Can-Fite BioPharma Ltd. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $28.1M +$1.4M +5.24% 31 Dec 2024 20-F 14 Apr 2025
Q4 2023 $26.7M +$149K +0.56% 31 Dec 2023 20-F 14 Apr 2025
Q4 2022 $26.5M -$2.12M -7.4% 31 Dec 2022 20-F 28 Mar 2024
Q4 2021 $28.6M -$7.26M -20.2% 31 Dec 2021 20-F 30 Mar 2023
Q4 2020 $35.9M +$6.36M +21.6% 31 Dec 2020 20-F 24 Mar 2022
Q4 2019 $29.5M +$5.2M +21.4% 31 Dec 2019 20-F 25 Mar 2021
Q4 2018 $24.3M 31 Dec 2018 6-K 01 Jun 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.